Effects of DMT on mental health outcomes in healthy volunteers

Earlier research has established that classic serotonergic psychedelics can improve a range of mental health outcomes, with most clinical work to date focusing on psilocybin, LSD and ayahuasca. N,N-Dimethyltryptamine (DMT) differs from these compounds in producing an especially intense but very short-lived acute experience when administered intravenously or smoked, and prior human work on DMT monotherapy is limited to very small samples or studies in which DMT is a component of ayahuasca. These features—short duration, distinctive phenomenology and limited human monotherapy data—mean that the therapeutic potential and mechanisms of IV DMT remain uncertain. Timmermann and colleagues set out to examine whether IV DMT alters negative psychological factors implicated in psychiatric disorders (depressive symptomatology, trait anxiety, and trait Neuroticism) and positive psychological factors (well-being, optimism, nature-relatedness, gratitude and meaning in life) in psychedelic‑experienced healthy volunteers. The paper reports two related datasets: a small single‑blind, placebo‑controlled study with fixed-order placebo then DMT, and a larger prospective dataset in which participants received DMT as part of an EEG–fMRI protocol. The investigators also tested whether the quality of the acute experience—measured as Oceanic Boundlessness—was associated with subsequent changes in depression and anxiety.

Two separate experimental datasets were collected from psychedelic‑experienced healthy volunteers recruited by word‑of‑mouth. Screening included physical tests, a psychiatric interview (including the MINI), and medical examination; main exclusions were psychedelic naivety, current or past psychiatric illness, family history of psychosis, excessive alcohol use, needle phobia or significant medical conditions. Across both studies 30 participants received IV DMT fumarate, but details of dropouts and sample sizes for specific analyses vary across the extracted text. The placebo‑controlled study was single‑blind with 13 volunteers (6 female, 7 male; mean age 34.76). Placebo (IV saline) was always administered in the first session and DMT in the second, with sessions separated by 7 days. As part of dose finding, four DMT doses were used (7, 14, 18 and 20 mg) delivered as a bolus IV injection (2 ml over 30 s, flushed with saline). Subjective DMT effects lasted on average 17 min with peak effects at 2–3 min. Mental health questionnaires were completed at baseline (one day before placebo), 1 week after placebo (5–7 days) and 1 week after DMT (6–9 days). Doses were collapsed for analysis due to sample size and plasma variability. The prospective EEG–fMRI study initially recruited 25 participants who underwent four dosing sessions across two days (two doses per day) in a pseudo‑balanced order; sessions were separated by approximately 2 weeks and two sessions on a day were separated by about 4 h. IV DMT (5 ml bolus over 30 s, flushed) and saline placebo (5 ml) were administered while participants wore an EEG cap inside an MRI scanner. Questionnaires for mental health outcomes were completed at baseline (one day prior to the first dosing session) and 2 weeks after the first dosing session (12–15 days). Because participants received both DMT and placebo during the same study visit, no placebo follow‑up measurement was obtainable in this cohort; the main comparisons therefore contrasted baseline versus 2‑week post‑DMT scores. Some participants dropped out or were excluded for motion or non‑attendance. Primary psychometric outcomes were QIDS‑SR16 for depressive symptoms, STAI‑T for trait anxiety and the Neuroticism scale of the NEO‑FFI. Secondary outcomes included WHO‑5 (well‑being), LOT‑R (optimism), GQ‑6 (gratitude) and the Meaning in Life Questionnaire. Acute effects were assessed with the 5D‑ASC and the Oceanic Boundlessness (OBN) dimension was used for hypothesis‑driven correlations with later changes in depression and anxiety. Statistical analyses were performed separately for each dataset: paired t‑tests (or Wilcoxon where data were non‑normal) compared post‑DMT versus placebo (placebo‑controlled) or post‑DMT versus baseline (prospective). To reduce floor/ceiling effects in healthy volunteers, participants scoring minimum/maximum values at placebo/baseline were excluded from certain comparisons; the extracted text indicates two exclusions from the placebo sample and three from the prospective sample for QIDS analyses. For primary outcomes no multiple comparisons correction was applied; Bonferroni correction was used for the secondary non‑clinical measures. Correlational analyses between OBN and change scores pooled participants from both studies to increase power, with one‑tailed significance thresholds specified for these hypothesis‑driven tests.

Primary outcome — depressive symptoms: In the placebo‑controlled sample, scores on the QIDS‑SR16 were significantly reduced 1 week after DMT compared with 1 week after placebo (reported statistic z[10] = -2.06, p = 0.027 two‑tailed, r = 0.67). There was no significant change between baseline and 1 week after placebo (z[10] = -0.29, p = 0.77). In the prospective sample, depressive symptoms were also reduced 2 weeks after DMT compared with baseline (t[13] = -3.24, p = 0.0065, d = 1.37). The extracted text does not give a fully consistent account of final analysed Ns across all tests; degrees of freedom are reported for the statistics above. Trait anxiety and Neuroticism: Trait anxiety did not reach statistical significance in either dataset, though medium effect sizes were reported. In the placebo‑controlled sample the comparison of 1 week post‑DMT versus 1 week post‑placebo yielded t[12] = 1.61, p = 0.13, d = 0.45; in the prospective sample the comparison of 2 weeks post‑DMT versus baseline yielded t[16] = -1.58, p = 0.13, d = 0.55. For Neuroticism, the placebo‑controlled sample showed a significant reduction after DMT versus placebo (t[12] = -2.60, p = 0.02, d = 0.72), but the prospective sample did not show a significant change (t[16] = -1.48, p = 0.16, d = 0.57). No significant differences were observed for placebo versus baseline in the placebo‑controlled dataset for these traits. Acute experience and associations with outcomes: Compared with placebo, DMT produced significantly higher scores on several 5D‑ASC dimensions including Oceanic Boundlessness (OBN), Dread of Ego‑Dissolution, Visual Restructuralization and Auditory Alterations (all p < 0.001), while Vigilance Reduction did not differ. Pooled correlational analyses across both studies found that higher OBN scores were associated with larger reductions in depression (r = -0.40, p = 0.026, one‑tailed) and trait anxiety (r = -0.38, p = 0.020, one‑tailed) assessed 1–2 weeks post‑DMT minus baseline. The investigators emphasise that pooling the datasets increases power but introduces heterogeneity due to differing doses and procedures. Positive psychological factors: Increases in nature‑relatedness and gratitude were observed when comparing DMT against baseline, but these effects did not survive correction for multiple comparisons. No significant changes were reported for well‑being (WHO‑5), optimism (LOT‑R) or meaning in life (MLQ) after correction. Other operational details: the acute subjective effects lasted on average 17 min with peak effects at 2–3 min post‑injection, and doses were collapsed in analyses due to small samples and plasma variability.

Timmermann and colleagues interpret their findings as tentative evidence that a single IV DMT administration can reduce depressive symptomatology in psychedelic‑experienced healthy volunteers, since reductions in QIDS‑SR16 scores were observed in both a small single‑blind placebo‑controlled study and a prospective sample. They further note a reduction in trait Neuroticism in the placebo‑controlled sample, and an association between the intensity of acute 'Oceanic Boundlessness' experiences and subsequent decreases in depression and trait anxiety, consistent with prior work implicating peak‑type experiences in therapeutic change with psychedelics. The investigators caution that several factors limit the generalisability and magnitude of the observed effects. Different doses used in the placebo‑controlled arm and methodological differences across studies introduce variability, and pooling datasets for correlational analyses reduces homogeneity. The prospective EEG–fMRI study design meant no placebo follow‑up was available, and both studies were conducted in neuroscience rather than therapeutic contexts (e.g. participants in scanners), which may blunt positive outcomes compared with therapeutic settings. The sample consisted of psychedelic‑experienced healthy volunteers rather than clinical populations; this carries potential ceiling/floor effects and led the team to exclude participants with extreme baseline scores for some analyses. The authors highlight that DMT's short duration and intensely unusual phenomenology might both constrain and shape therapeutic utility: brief exposures may be advantageous for scalability and flexible dosing but may also limit the time available for psychological insight unless infusion methods are adjusted or integration is strengthened. Neurobiological mechanisms are discussed briefly: like other classical psychedelics, DMT is primarily a 5‑HT2A agonist and may facilitate therapeutic effects by promoting cortical plasticity that allows revision of entrenched cognitive and behavioural patterns when combined with psychological support. The authors call for further research in clinical populations to determine consistent safety and efficacy profiles, to explore dose and infusion strategies that lengthen the experience if needed, and to investigate psychological mechanisms such as insight, emotional breakthrough and psychological flexibility in relation to DMT outcomes. A number of study‑level limitations are reiterated, including potential regression to the mean, floor effects in healthy samples, and the need for therapeutic contexts and clinical trials to fully characterise DMT's potential.